Biotech Stocks At 52-Week Highs - KOD, MASS, OBIO, CDNA, PMVP
Several biotech stocks, including Kodiak Sciences (KOD), 908 Devices (MASS), Orchestra BioMed (OBIO), CareDx (CDNA), and PMV Pharmaceuticals (PMVP), reached 52-week highs on October 1, 2026. These gains were primarily driven by positive clinical trial results, strong financial performance, and breakthrough device designations from the FDA for their respective therapies and technologies. The companies operate in diverse areas such as retinal diseases, chemical analysis, vascular conditions, transplant diagnostics, and oncology.
A 10% owner sells 18,000 shares of 908 Devices (MASS) at an average $11.5179 each.
AWM Investment Company, a 10% owner of 908 Devices Inc. (MASS), sold 18,000 common shares indirectly at a weighted average price of $11.5179 per share on September 29, 2026. Following this transaction, AWM's reported indirect position in the company is 4,736,773 shares. The sale, detailed in a Form 4 filing, indicates a negative sentiment and moderate impact, with AWM disclaiming beneficial ownership except for its pecuniary interest.
Form 4 908 Devices Inc For: 26 September By Investing.com
This article announces the filing of Form 4 by 908 Devices Inc. for transactions that occurred on September 26. It is a brief news item published by Investing.com, providing basic information about the regulatory filing. The content itself is very short and simply states the fact of the filing.
Awm investment sells $283k in 908 Devices stock By Investing.com
AWM Investment Company, a significant shareholder and director of 908 Devices Inc., recently sold common stock valued at $283,875. These transactions involved 25,000 shares sold over two days in late September 2026, at prices ranging from $11.25 to $11.3594 per share. The sales occurred while the stock was near its 52-week high, with InvestingPro data suggesting it is overvalued despite a 117% year-to-date return.
Form 4 908 Devices Inc For: 26 September By Investing.com
This article reports on the filing of Form 4 for 908 Devices Inc. on September 26, 2026. The Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. The brief news piece indicates that this filing is now available for public review.
Awm investment sells $283k in 908 Devices stock By Investing.com
AWM Investment Company, Inc., a significant owner of 908 Devices Inc. (NASDAQ:MASS), sold 25,000 shares of common stock for a total of $283,875 in late September 2026. These transactions occurred as the stock was trading near its 52-week high, with InvestingPro indicating it might be overvalued despite a 117% year-to-date return. Following the sale, AWM Investment Company still beneficially owns over 4.7 million shares of 908 Devices.
A 10% owner sold 1,000 and 24,000 shares of 908 Devices (MASS) on consecutive days.
AWM Investment Company, Inc., a 10% owner of 908 Devices Inc. (MASS), reported two indirect sales of common stock. On September 23, 2026, 1,000 shares were sold at $11.25 each, and on September 24, 2026, 24,000 shares were sold at $11.3594 each, totaling 25,000 shares sold for approximately $284K. Following these transactions, AWM Investment Company's reported holdings were 4,754,773 shares.
Roth MKM Maintains 908 Devices(MASS.US) With Buy Rating, Raises Target Price to $14
Roth MKM has reiterated its Buy rating on 908 Devices (MASS.US) and increased its price target to $14. This positive revision from the analyst firm indicates continued confidence in the company's performance and future prospects. Investors may view this as a favorable outlook for 908 Devices' stock.
908 Devices Inc Lobbyists, 2025
This OpenSecrets page details the lobbying activities for 908 Devices Inc. in 2025. The company spent $95,000 on federal lobbying, exclusively direct spending. Two lobbyists were named, both with prior federal government experience, and they were employed by Brendan Neal Strategies and National Group LLP.
Canaccord initiates 908 Devices stock coverage with buy rating By Investing.com
Canaccord has initiated coverage on 908 Devices Inc. (NASDAQ:MASS) with a buy rating and a price target of $13.50. The company, which specializes in handheld chemical analysis equipment for defense and public safety, has seen its stock surge by 84.57% year-to-date, though InvestingPro suggests it may be overvalued. This follows recent positive revenue growth and a price target increase from Stifel, despite a wider-than-expected loss per share in the last quarter.
908 Devices Insider Christopher D. Brown Sells 30,000 Shares at $10.58 on September 2, 2026 (NASDAQ: MASS)
908 Devices Inc. insider Christopher D. Brown sold 30,000 shares of the company's stock at $10.58 per share on September 2, 2026. Following this transaction, Brown's remaining ownership in 908 Devices (NASDAQ: MASS) stands at 775,559 shares. This sale provides insight into the insider trading activity and Brown's current stake in the company.
908 Devices: director Brown sells $317,400 of common stock By Investing.com
Christopher D. Brown, a Director at 908 Devices Inc. (NASDAQ:MASS), recently sold 30,000 shares of common stock for $317,400 under a Rule 10b5-1 trading plan. Following the sale, Mr. Brown still beneficially owns 775,559 shares. This insider sale occurs as the stock has shown significant momentum, despite InvestingPro analysis suggesting it may be overvalued.
Director at 908 Devices (NASDAQ: MASS) sells 30,000 shares under 10b5-1 plan
A director at 908 Devices Inc. (NASDAQ: MASS), Christopher D. Brown, sold 30,000 shares of common stock on September 2, 2026, at a weighted average price of $10.58 per share. This sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following the transaction, Brown directly holds 775,559 shares of the company.
908 Devices: director Brown sells $317,400 of common stock
Christopher D. Brown, a director at 908 Devices Inc. (NASDAQ:MASS), recently sold 30,000 shares of common stock totaling $317,400, executed under a Rule 10b5-1 trading plan. Despite the insider sale, the stock has shown significant momentum with a 91% year-to-date return, though InvestingPro analysis suggests it may be overvalued. The company recently reported stronger-than-expected Q2 2026 revenue and raised its full-year sales outlook, leading Stifel to increase its price target and maintain a Buy rating.
908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
908 Devices Inc. (Nasdaq: MASS) announced its participation in the 32nd Annual Gabelli Aerospace & Defense Symposium on September 10, 2026, in New York City. Company management is scheduled to present at 3:45 p.m. Eastern Time, with a webcast registration available through Gabelli's website. An archived webcast will be accessible on the company's investor relations website approximately one week after the event.
908 Devices (MASS) officer plans $125K stock sale
Joseph Griffith, an officer at 908 Devices Inc. (MASS), has filed a Rule 144 notice to sell 11,459 shares of common stock, valued at approximately $125,132. The shares were acquired through the vesting of restricted stock units between February 2025 and February 2026. This filing also references a previous 10b5-1 sale of 6,940 shares on May 28, 2026.
AWM Investment Company, Inc. Trims 908 Devices Inc (MASS) Stake
AWM Investment Company, Inc. has reduced its stake in 908 Devices Inc (MASS) by 50,000 shares, a 1.04% decrease in its position, despite the stock's significant year-to-date appreciation. The firm maintains a substantial holding in 908 Devices, which is considered "Significantly Overvalued" by GuruFocus with weak profitability metrics but strong financial health and momentum. This modest reduction reflects a cautious approach to risk management given the stock's current valuation and recent surge.
AWM trims 50,000-share stake in 908 Devices Inc. (MASS) stock
AWM Investment Company, Inc., a ten percent owner of 908 Devices Inc. (MASS), indirectly sold 50,000 shares of common stock on August 20-21, 2026, through limited partnerships it advises. The sales occurred at weighted average prices between $10.52 and $10.61 per share. AWM disclaims beneficial ownership except for its pecuniary interest, as detailed in the Form 4 filing.
908 Devices (MASS) Q2 2026 Earnings Call Transcript
908 Devices (MASS) reported strong Q2 2026 results, with total revenue up 23% year-over-year to $16.1 million, driven by increased product volume for VipIR and the addition of NIRLAB revenue. The company significantly improved its Adjusted EBITDA loss by 50% to $1.9 million and raised its full-year 2026 revenue guidance to $68 million to $70 million. Key growth drivers include strong performance in U.S. state and local markets, strategic acquisition of NIRLAB, and increasing demand for its detection technologies, despite delays in the U.S. military's AVCAD program.
908 Devices (MASS) Q2 2026 Earnings Call Transcript
908 Devices (MASS) reported strong Q2 2026 earnings with 23% revenue growth to $16.1 million, driven by increased product volume for VipIR and the acquisition of NIRLAB. The company saw a 50% improvement in adjusted EBITDA loss, reducing it to $1.9 million. Key drivers included robust demand from U.S. state and local agencies, successful integration of NIRLAB, and strategic expansion of its infrared detection devices.
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
908 Devices, following the divestiture of its life-sciences business, is now exclusively focused on handheld chemical and drug detection technologies for public safety and defense markets. The company's products, including the MX908, VipIR, and NIRLab, offer rapid field analysis for synthetic opioids, toxic chemicals, and drug screening, addressing issues like lab backlogs and immediate response needs. With manufacturing capacity to scale and plans for a next-generation MX908, the company sees significant market opportunities and has a solid financial runway for growth.
908 Devices CEO Knopp sells $283,677 in common stock
Kevin J. Knopp, CEO of 908 Devices Inc. (NASDAQ: MASS), sold 27,622 shares of company stock for a total of approximately $283,677 through a Rule 10b5-1 trading plan. These sales occurred as the stock neared its 52-week high and InvestingPro analysis indicated the stock might be overvalued and in overbought territory. Despite this, the company recently reported better-than-expected Q2 2026 revenue and raised its full-year sales outlook, leading Stifel to increase its price target.
908 Devices (NASDAQ:MASS) Qualifies for Minervini Trend Template and High-Growth Momentum Screen
908 Devices (NASDAQ:MASS) has qualified for both the Minervini Trend Template and a high-growth momentum screen, indicating strong technical and fundamental performance. The company exhibits a confirmed uptrend with aligned moving averages and high relative strength, alongside improving revenue and EPS growth. While the stock shows strong trends, its setup quality for immediate entry is low due to recent volatility, suggesting a potential waiting period for a better entry point.
908 Devices (MASS) CEO offloads 27K shares under preset 10b5-1 plan
Kevin J. Knopp, President and CEO of 908 Devices Inc. (MASS), sold a total of 27,622 shares of common stock in August 2026 under a pre-established Rule 10b5-1 trading plan. The sales occurred on August 13 and August 17, at weighted average prices of $10.06 and $10.35 per share, respectively. An additional 541,223 shares are held indirectly by The Kevin J. Knopp Irrevocable Trust of 2018, where Knopp may be deemed a beneficial owner.
908 Devices CEO Knopp sells $283,677 in common stock
Kevin J. Knopp, CEO of 908 Devices Inc., sold 27,622 shares of company stock for approximately $283,677 through a pre-arranged trading plan in August 2026. These sales occurred as the stock neared its 52-week high, with the RSI suggesting overbought conditions. Despite the insider sales, the company recently reported better-than-expected Q2 2026 revenue and raised its full-year sales outlook, leading Stifel to increase its price target to $12.00.
908 Devices (NASDAQ: MASS) founder lines up new stock sale
Kevin Knopp, the founder of 908 Devices (NASDAQ: MASS), has filed a Form 144 to sell up to 20,000 shares of MASS common stock through Merrill Lynch. These shares are founder shares acquired in 2012. The filing also notes Knopp's previous sales of smaller blocks of common stock over the last three months, with the company having 37,813,621 shares outstanding as of August 17, 2026.
908 devices director Christopher Brown sells $169,800 in shares By Investing.com
Christopher D. Brown, a director at 908 Devices Inc. (NASDAQ:MASS), sold 20,000 shares of the company’s common stock for $169,800 on August 5, 2026, under a Rule 10b5-1 trading plan. Despite the sale, the stock has since rallied, trading above its Fair Value and near its 52-week high, with strong year-to-date performance. The company also reported stronger-than-expected Q2 2026 revenue, leading Stifel to raise its price target to $12.00 while maintaining a Buy rating.
908 devices director Christopher Brown sells $169,800 in shares
Christopher D. Brown, a director at 908 Devices Inc. (NASDAQ:MASS), sold 20,000 shares of company stock worth $169,800 on August 5, 2026, through a Rule 10b5-1 trading plan. Following the sale, Mr. Brown still holds 823,359 shares, and the stock has since rallied to $10.01. InvestingPro analysis indicates that MASS is trading above its Fair Value and has seen over 90% year-to-date gains, with Stifel raising its price target to $12.00 after the company reported stronger-than-expected Q2 2026 revenue.
Dimensional Fund Advisors LP Has $726,000 Stake in 908 Devices Inc. $MASS
Dimensional Fund Advisors LP significantly reduced its stake in 908 Devices Inc. by 51.8% in the first quarter, now holding 118,751 shares valued at $726,000. Despite the reduction, institutional investors collectively own a substantial 88.06% of the company. 908 Devices surpassed analyst expectations for revenue and EPS in its latest earnings report, though it remains unprofitable with a negative net margin.
908 Devices Inc. (MASS) Stock News Today
This article provides recent news and financial updates for 908 Devices Inc. (MASS). The company's stock closed at $10.010 with a slight decrease. Key news includes their Q2 2026 earnings report, showing a 23% increase in revenue and a narrowing EBITDA loss.
AWM Investment Company reports 11.8% 908 Devices (MASS) ownership through Special Situations funds
AWM Investment Company has reported an 11.8% ownership stake in 908 Devices (MASS) through its Special Situations funds, as detailed in a recent SCHEDULE 13G/A SEC filing. This beneficial ownership amounts to 4,879,773 shares, with AWM holding sole voting and dispositive power over these shares distributed among various funds. David M. Greenhouse and Adam C. Stettner are identified as controlling principals of AWM and the general partners of the funds involved.
ARK Investment Management (MASS) reports 2.0M-share, 5.32% holding in 908 Devices
ARK Investment Management LLC and its CEO/CIO, Catherine D. Wood, have reported a beneficial ownership of 2,027,920 shares of 908 Devices Inc. common stock, which represents 5.32% of the outstanding class. The disclosure, filed as a Schedule 13G/A, indicates that ARK has sole voting and dispositive power over these shares, while Catherine D. Wood reports shared voting and dispositive power. The filing also notes that no other ARK client exceeds a 5% interest in these securities, with the exception of the ARK Genomic Revolution ETF.
908 Devices (MASS) Stock Price Stalls As Handheld Growth Meets Loss Concerns
908 Devices (MASS) saw its stock price remain largely flat despite reporting a strong quarter in handheld revenue growth. While revenue increased and the adjusted EBITDA loss narrowed, concerns persist regarding the company's path to sustained profitability, heavy government exposure, and the lower margins of some upcoming orders. The article questions whether the current valuation is justified given the mix of growth and ongoing losses.
Stifel raises 908 Devices stock price target on Q2 beat, guidance
Stifel raised its price target for 908 Devices Inc. (NASDAQ:MASS) to $12.00 from $10.00, maintaining a Buy rating, following the company's strong second-quarter performance and revised full-year guidance. The analyst noted positive business momentum, expanding adoption opportunities, and an expected 23% revenue growth in fiscal 2026, despite some uncertainties regarding high-profile contract work. 908 Devices reported a 23% increase in Q2 2026 revenue to $16.1 million, exceeding forecasts, though it posted a wider-than-expected adjusted loss per share.
908 Devices Inc (MASS) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised ...
908 Devices Inc. (MASS) reported strong Q2 2026 results with a 23% revenue increase to $16.1 million, driven by demand from US state and local customers. The company significantly improved profitability, cutting adjusted EBITDA loss by over 50% year-over-year, and raised its full-year 2026 revenue guidance to $68 million to $70 million. Key drivers include successful integration of NirLab, market share gains by VipIR, and a major ProtectIR order, despite some uncertainties with the AVCAD military program and modest recurring revenue growth.
Christopher Brown Sells 8,358 Shares of 908 Devices (NASDAQ:MASS) Stock
908 Devices Director Christopher Brown sold 8,358 shares of the company's stock for $77,144, reducing his ownership by 1.03%. This sale occurred under a pre-arranged Rule 10b5-1 plan. The company recently reported better-than-expected quarterly revenue and adjusted EPS, and raised the lower end of its 2026 revenue guidance, despite remaining unprofitable.
908 Devices (MASS) CEO Knopp sells 149K shares, reports 541K held via trust
Kevin J. Knopp, President and CEO of 908 Devices Inc. (MASS), reported selling 149,013 shares of common stock between August 10 and 12, 2026, under a Rule 10b5-1 trading plan. The sales occurred at weighted average prices ranging from $9.06 to $10.16 per share. Additionally, Knopp indirectly holds 541,223 shares through The Kevin J. Knopp Irrevocable Trust of 2018, where his brother-in-law acts as trustee with sole voting and dispositive control.
908 Devices (MASS) director Brown sells 17,800 shares in Rule 10b5-1 trades
908 Devices Inc. director Christopher D. Brown sold a total of 17,800 shares of common stock in two open-market transactions on August 10 and August 11, 2026. These sales, executed under a Rule 10b5-1 trading plan adopted in November 2025, involved weighted average prices of $9.03 and $9.23 per share, respectively. Following these transactions, Brown retains 805,559 shares of common stock in the company.
908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
908 Devices Inc. announced that its CEO and CFO will present at the 17th Annual Midwest IDEAS Conference on August 26, 2026. The company, which specializes in handheld chemical analysis tools, will host investor meetings and webcast its presentation. This event provides an opportunity for investors to learn more about 908 Devices' technology and applications in health, safety, and defense.
908 Devices Reports Loss for Q2 2026, Misses Estimates
908 Devices Inc. (NASDAQ: MASS) reported a wider-than-expected Q2 2026 loss of $0.32 per share, missing consensus estimates of a $0.17 loss, despite revenue growing 23.0% year-over-year to $16.1M. The company's net loss was $11.9M due to investments in commercial infrastructure and product development, while its installed base of devices expanded to 4,101. Management provided full-year revenue guidance of $68.0M to $70.0M, and shares saw a muted reaction, indicating investor focus on long-term growth.
908 Devices Q2 2026 slides: 23% growth, profitability in sight
908 Devices Inc. reported a 23% year-over-year revenue growth in Q2 2026, exceeding Wall Street expectations, with revenue reaching $16.1 million. The company is nearing profitability, with management raising full-year 2026 revenue guidance to $68 million-$70 million and projecting positive adjusted EBITDA of $0.7 million in Q4 2026. This growth is driven by its focus on handheld chemical detection solutions, propelled by increasing global threats like the opioid crisis and rising defense spending, and bolstered by the recent acquisition of NIRLab.
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) reported a Q2 loss of $0.11 per share, outperforming the Zacks Consensus Estimate of a $0.14 loss, and marking a +21.43% earnings surprise. The company's revenues reached $16.07 million, surpassing estimates by 5.92% and showing growth from $13.03 million a year ago. Despite market outperformance year-to-date, the stock currently holds a Zacks Rank #3 (Hold), indicating it's expected to perform in line with the market.
908 Devices (MASS) lifts 2026 revenue guidance after 23% Q2 sales growth
908 Devices Inc. (MASS) reported a strong Q2 2026 with revenue up 23% year-over-year to $16.1 million, driven by VipIR product demand and NIRLab contributions. The company also raised the low end of its full-year 2026 revenue guidance to $68.0–$70.0 million, representing 21%–25% growth over 2025. Despite a net loss from continuing operations of $11.9 million, its adjusted EBITDA loss significantly narrowed to $1.9 million, and it maintains a strong cash position of $101.5 million with no debt.
908 Devices Q2 2026 earnings: Revenue rises 23% as EBITDA loss narrows
908 Devices (NASDAQ: MASS) reported Q2 2026 revenue of $16.1 million, a 23% increase year-over-year, with its adjusted EBITDA loss significantly narrowing to $1.9 million. This improvement was driven by product sales growth and the NIRLab acquisition. Despite positive operational momentum and a strong balance sheet, the company remains unprofitable on a GAAP basis due to high operating expenses and acquisition-related costs.
908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
908 Devices Inc. reported strong second-quarter 2026 financial results, with revenue increasing 23% year-over-year to $16.1 million and Adjusted EBITDA loss more than halved. The company also raised the low end of its full-year 2026 revenue outlook to $68.0 million, reflecting 21% to 25% growth. Key drivers included strong performance in the U.S. state and local market, with significant adoption of its VipIR product and the introduction of NIRLab.
908 Devices Inc. 2026: Revenue $16.07M, EPS ($0.32) — 10-Q Summary
908 Devices Inc. reported Q2 2026 results with revenue of $16.07 million, a 23.3% increase year-over-year, and a narrowed net loss of ($11.89 million). Diluted loss per share improved to ($0.32) from ($0.37) in the prior-year quarter. Revenue growth was driven by higher device sales and expanded recurring revenue, with product sales now accounting for 69% of total revenue.
908 Devices Secures $6M ProtectIR Order From Asia-Pacific Corrections Agency
908 Devices Inc. (Nasdaq: MASS) reported strong second-quarter 2026 financial results, with revenue increasing 23% year-over-year to $16.1 million and adjusted EBITDA loss narrowing by more than half. The company secured a $6 million ProtectIR order from an Asia-Pacific corrections agency and raised the lower end of its full-year 2026 revenue outlook to $68.0 million to $70.0 million, reflecting continued growth in its chemical analysis tools market.
MASS (MASS) investor Christopher Brown plans 100,000-share stock sale
Christopher Brown, an investor in MASS, has filed a Form 144 to sell 100,000 shares of MASS common stock, valued at $888,000.00. These shares were originally acquired as founder's shares and will be sold through Morgan Stanley Smith Barney LLC. The filing also notes prior sales made by Brown under a Rule 10b5-1 trading plan.
908 Devices | 4: Statement of changes in beneficial ownership of securities-Director Brown Christopher D.
This document is a statement of changes in beneficial ownership of securities for Director Christopher D. Brown of 908 Devices. It reports transactions related to his holdings in the company.
Insider Selling: 908 Devices (NASDAQ:MASS) Director Sells $169,800.00 in Stock
908 Devices (NASDAQ:MASS) Director Christopher Brown sold 20,000 shares of the company's stock on August 5th for $169,800. This transaction, executed under a pre-arranged Rule 10b5-1 trading plan, reduced his ownership by 2.37% to 823,359 shares. The stock is currently trading at $8.88, near its 12-month high, and has a mixed analyst sentiment with an average "Hold" rating.
